Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

We recently compiled a list of the 10 Under-the-Radar Stocks with Massive Upside for 2025. In this article, we are going to take a look at where Novavax, Inc. (NYSE:NVAX) stands against other ...

According to the 6 industry analysts covering Novavax, the consensus is that breakeven is near. They anticipate the company to incur a final loss in 2024, before generating positive profits of US$82m ...

In the most recent trading session, Novavax (NVAX) closed at $8.45, indicating a +0.24% shift from the previous trading day.

After two years characterized by layoffs, pipeline reorganizations, FDA delays and clinical holds, Novavax CEO John Jacobs ...

Dynavax should take a leaf from its vaccine maker peer, Novavax, and work to monetize its CpG1018 adjuvant. Learn more about ...

Shares of vaccine companies fell on Tuesday after a Senate panel voted to advance Robert F. Kennedy Jr.'s nomination to lead ...

The most recent trading session ended with Novavax (NVAX) standing at $9.34, reflecting a +1.3% shift from the previouse trading day's closing. The stock outpaced the S&P 500's daily loss of 1.46%.

Novavax (NVAX) closed at $9.34 in the latest trading session, marking a +1.3% move from the prior day. The average of price targets set by Wall Street analysts indicates a potential upside of 81.6% in ...

SINGAPORE - People who are eligible for the Novavax Covid-19 vaccine can go to selected clinics from Jan 24 to April 30 for ...